MedTrace Logo

Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome

NCT02503865 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2015-11-30

Study results available
· View outcomes & findings →

Summary

Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin

Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day

DIETARY_SUPPLEMENT

"Analimentary detoxication"

Vegetable and salt diet

Sponsors & Collaborators

  • Institute Of Cardiology & Internal Diseases, Kazakhstan

    collaborator OTHER_GOV

  • Nazarbayev University

    lead OTHER

Principal Investigators

  • Tabynbayev Nariman, Professor · Nazarbayev University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-12-31
Completion
2014-12-31

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02503865 on ClinicalTrials.gov